Breast cancer research takes a significant stride forward as Professor Semin Lee and his research team from the Department of Biomedical Engineering at UNIST, in collaboration with Professor Ji-Yeon Kim and Professor Young-Hyuck Im from the Division of Hematology-Oncology at Samsung Medical Center in Seoul, delves into the exploration of triple-negative apocrine carcinoma. This rare breast cancer subtype has garnered attention due to its unique genetic characteristics and improved prognosis when compared to other forms of triple-negative breast cancer (TNBC).
Triple-negative apocrine carcinoma accounts for only 1-4% of all breast cancers. While it falls under the category of TNBC, which is characterized by the absence of hormone receptors and epidermal growth factor receptors, this particular subtype exhibits a more favourable prognosis than other TNBC subtypes. However, due to limited analysis studies on triple negative apocrine carcinoma, treatment criteria have remained ambiguous.
In their study titled ‘Multiple Omics Study of Triple-Negative Apocrine Carcinoma,’ the research team employed advanced molecular biological methods to conduct multi-omics analyses—integrating genetic information and RNA molecules—to unravel novel insights into this rare form of breast cancer.
The findings revealed distinct genomic characteristics that impact the prognosis for patients with triple-negative apocrine carcinoma. The researchers identified four to five unique subtypes within breast cancer based on gene expression profiles. Notably, patients with triple-negative apocrine carcinoma exhibited similarities to Luminal A—a subtype associated with better prognostic outcomes. The study confirmed an impressive five-year disease-free survival rate for these patients at 92.2%, significantly higher than those diagnosed with other types of TNBC (59.1%).
“This research has the potential to guide treatment decisions regarding adjuvant chemotherapy after surgery and predict patient survival outcomes,” explained Sabin Park (Department of Biomedical Engineering, UNIST), first author of the study, while emphasizing the potential impact of these findings.
Published in the journal, Experimental & Molecular Medicine, this study received support from the Korea Research Foundation’s Cancer Control Research Center by Intercellular Signal Communication—a program under the Ministry of Science and ICT.
As breast cancer continues to be a significant global health concern affecting millions of lives, studies like these play a crucial role in advancing personalized treatment approaches based on specific genetic mutations. The groundbreaking insights gained from Professor Lee’s team provide hope for improved clinical management and better prognostic outcomes for patients diagnosed with triple negative apocrine carcinoma.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.